

Childhood cancer: Indication for genetic counseling?*

*updated Jongmans criteria [Jongmans et al., 2016]

if at least one criterion is fulfilled, your patient may benefit from genetic counseling

1. Family history (3 generation pedigree)

- ≥2 malignancies occurred in family members before age 18 years, including index patient
- Parent or sibling with current or history of cancer before age 45 years
- ≥2 first or second degree relatives in the same parental lineage with cancer before age 45 years
- The parents of the child with cancer are consanguineous

2. One of the following Neoplasms was diagnosed:

- | | |
|--|---|
| <ul style="list-style-type: none"> <input type="checkbox"/> Adrenocortical carcinoma / adenoma <input type="checkbox"/> ALL (low hypodiploid) <input type="checkbox"/> ALL (ring chromosome 21) <input type="checkbox"/> ALL (Robertsonian translocation 15;21) <input type="checkbox"/> ALL relapse (<i>TP53</i> mutated) <input type="checkbox"/> AML (Monosomy 7) <input type="checkbox"/> Basal cell carcinoma <input type="checkbox"/> Botryoid rhabdomyosarcoma of the urogenital tract (fusion-negative) <input type="checkbox"/> Chondromesenchymal hamartoma <input type="checkbox"/> Choroid plexus carcinoma / tumor <input type="checkbox"/> Colorectal carcinoma <input type="checkbox"/> Cystic nephroma <input type="checkbox"/> Endolymphatic sack tumor <input type="checkbox"/> Fetal rhabdomyoma <input type="checkbox"/> Gastrointestinal stromal tumor <input type="checkbox"/> Glioma of the optic pathway (with signs of NF1) <input type="checkbox"/> Gonadoblastoma <input type="checkbox"/> Hemangioblastoma <input type="checkbox"/> Hepatoblastoma (<i>CTNNB1</i> wildtype) <input type="checkbox"/> Hepatocellular carcinoma <input type="checkbox"/> Infantile myofibromatosis <input type="checkbox"/> Juvenile myelomonocytic leukemia <input type="checkbox"/> Keratocystic odontogenic tumor <input type="checkbox"/> Large cell calcifying Sertoli-cell-tumor <input type="checkbox"/> Malignant peripheral nerve sheath tumor <input type="checkbox"/> Medullary thyroid carcinoma <input type="checkbox"/> Medulloblastoma (SHH activated) <input type="checkbox"/> Medulloblastoma (WNT activated, <i>CTNNB1</i> wildtype) | <ul style="list-style-type: none"> <input type="checkbox"/> Medullary renal cell carcinoma <input type="checkbox"/> Medulloepithelioma <input type="checkbox"/> Melanoma <input type="checkbox"/> Meningioma <input type="checkbox"/> Myelodysplastic syndrome <input type="checkbox"/> Myeloproliferative neoplasms (except CML) <input type="checkbox"/> Myxoma <input type="checkbox"/> Neuroendocrine tumor <input type="checkbox"/> Paraganglioma / pheochromocytoma <input type="checkbox"/> Parathyroid carcinoma / adenoma <input type="checkbox"/> Pineoblastoma <input type="checkbox"/> Pituitary adenoma / tumor <input type="checkbox"/> Pituitary blastoma <input type="checkbox"/> Pleuropulmonary blastoma <input type="checkbox"/> Renal cell carcinoma <input type="checkbox"/> Retinoblastoma <input type="checkbox"/> Rhabdoid tumor <input type="checkbox"/> Rhabdomyosarcoma with diffuse anaplasia <input type="checkbox"/> Schwannoma <input type="checkbox"/> Schwannomatosis <input type="checkbox"/> Sertoli-Leydig cell tumor <input type="checkbox"/> Sex cord stromal tumor with annular tubules <input type="checkbox"/> Small cell carcin. of the ovary hypercalcemic type <input type="checkbox"/> Squamous cell carcinoma <input type="checkbox"/> Subependymal giant cell astrocytoma <input type="checkbox"/> Thyroid carcinoma (non-medullary) <input type="checkbox"/> Transient myeloproliferative disease <input type="checkbox"/> Other rare cancers or cancers that typically occur in adults, unusually early manifestation age |
|--|---|

3. Genetic tumor analysis reveals defect suggesting a germline predisposition

4. A patient with ≥2 malignancies (e.g. secondary, bilateral, multifocal, metachronous)

5. A child with cancer and congenital or other anomalies

Sign	Think of
<input type="checkbox"/> Congenital anomalies	Abnormal organs, skeletal anomalies, oral clefting, abnormal teeth, urogenital anomalies, abnormal hearing or vision, etc.
<input type="checkbox"/> Facial dysmorphism	
<input type="checkbox"/> Mental impairment, developmental delay	Abnormal behavior, learning difficulties
<input type="checkbox"/> Abnormal growth	Height, head circumference, birth weight, hemihyperplasia, growth chart
<input type="checkbox"/> Skin anomalies	Abnormal pigmentation such as ≥2 café-au-lait spots, vascular lesions, hypersensitivity to sun, benign tumors, etc.
<input type="checkbox"/> Hematological abnormalities (not explained by current cancer)	Pancytopenia, anemia, thrombocytopenia, neutropenia, leukopenia, macrocytic erythrocytes
<input type="checkbox"/> Immune deficiency	Frequency of infections, lymphopenia
<input type="checkbox"/> Endocrine anomalies	Primary hyperparathyroidism, precocious puberty, gigantism/acromegaly, Cushing syndrome

6. The patient suffers from excessive toxicity of cancer therapy